Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer

Launched by MAYO CLINIC · Jan 11, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on collecting samples and information from patients with recurrent or metastatic breast cancer, including male breast cancer. The goal is to better understand how these types of cancer develop and progress, which can help improve treatment options in the future. The study is currently recruiting participants who are at least 18 years old and have a confirmed diagnosis of invasive breast cancer, either through a biopsy for women or through a biopsy-proven diagnosis for men.

If you join this trial, you can expect to provide some samples and clinical information, which will be used to create a valuable resource for research. It's important to note that to be eligible, you should be able to understand the study and agree to participate by signing a consent form. However, individuals with certain conditions, such as serious mental health issues or severe allergies to local anesthetics, may not be able to participate. This study aims to help improve care for patients like you, so your involvement could make a difference in future treatment approaches.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Female participants must have histologically or cytologically confirmed invasive breast cancer.
• • Male participants must have biopsy proven breast cancer.
• • Age must be \>= 18 years, and all must be able to understand and willing to sign an informed consent document.
• Exclusion Criteria:
• • Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent; a history of serious or life-threatening allergic reaction to local anesthetics (i.e. lidocaine, xylocaine).
• • Any other condition, which in the opinion of the patient's treating oncologist, or the physician performing the biopsy procedure, would make participation in this protocol unreasonably hazardous for the patient.